Abstract 1120
Background
Brigatinib is a next-generation ALK inhibitor with activity against a broad range of ALK mutations and ROS1 rearrangements. It is approved for use post-crizotinib in ALK+ mNSCLC based on phase II trial (ALTA) data, and significantly improved progression-free survival (PFS) vs crizotinib (HR = 0.49) in ALK TKI-naïve patients (pts) in the phase III ALTA-1L trial. UVEA-Brig captures detailed information about brigatinib therapy in a real-world situation.
Methods
UVEA-Brig is a retrospective analysis of data from pts who started brigatinib between 06/16 and 12/17 in Italy, Norway, Spain and the UK in an expanded access program (EAP). Due to legislation in Italy, only data for deceased pts and pts who had been followed up for 18 months could be used. Adults with mNSCLC, including those with brain lesions, who are resistant to or intolerant of at least one prior ALK inhibitor and have ECOG performance status ≤3 are eligible. The primary objective is to describe baseline characteristics, prior therapy, clinical outcomes and safety with brigatinib.
Results
Data for 50 pts are available (male: 40%; never smoker: 54%; adenocarcinoma: 94%: stage IV at diagnosis: 92%; median age: 51 [31–78] years; brain lesions at study entry: 60% [46% irradiated]). Median follow-up 6 (range 0–24) months. Pts had received a median of 2 (range 1–6) lines of prior systemic therapy (≥3 lines: 34%), with a median of 1 (1–5) prior ALK TKI (crizotinib 84%; ceritinib 46%; alectinib 10%; lorlatinib 8%). 36 pts have discontinued brigatinib (progression: 25; adverse events: 3 [pneumonitis, amylase and creatine kinase increase, and asthenia/fatigue]). 43 pts were evaluable for best response: complete response: 1 (2.3%); partial response: 14 (32.6%); stable disease: 20 (46.5%) (response rate: 34.9%; disease control rate: 81.4%). Median response duration was 9.7 (range 0.7–23.4) months. Median PFS was 5.7 (95% CI 6.2–9.9) months; median OS was 10.2 (8.6–12.6) months. 20 pts received subsequent therapies; 17 had an ALK inhibitor, most commonly lorlatinib (n = 10).
Conclusions
These data from daily clinical practice support the activity of brigatinib also in pts with heavily pretreated ALK+ mNSCLC.
Clinical trial identification
Editorial acknowledgement
Andrew Noble, Bioscript Group.
Legal entity responsible for the study
Takeda.
Funding
Takeda.
Disclosure
S. Novello: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda, BMS, Moehringer Ingelheim, Eli Lilly, Celgene, Pfizer, Roche, AstraZeneca, MSD, AbbVie. O.T. Brustugun: Honoraria (institution): Takeda. J. Cadranel: Advisory / Consultancy: Takeda; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Roche. F. Griesinger: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Takeda; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Siemens; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ariad; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie. M.J. Hochmair: Honoraria (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self): Pfizer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Takeda; Advisory / Consultancy: Novartis. M. Pérol: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda. S. Popat: Honoraria (self), Research grant / Funding (institution): BMS, Roche, Takeda, Pfizer, MSD, EMD Serono, Boehringer Ingelheim; Honoraria (self): Chugai, Novartis, Guardant Health, AbbVie, Medscape, Tesaro, OncLive, AstraZeneca; Research grant / Funding (institution): Bayer, Celgene, Synta, Clovis Oncology, Eli Lilly, Epizyne, Ariad; Research grant / Funding (self): Elsevier. N. Bent-Ennakhil: Full / Part-time employment: Takeda. C. Kruhl: Full / Part-time employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
5519 - Is there a difference of Palliative care problems and needs between cancer and non-cancer hospitalized elderly patients?
Presenter: Ioanna Chatzi
Session: Poster Display session 1
Resources:
Abstract
2505 - There is a lack of clinical research for patients with cancer in palliative care
Presenter: Marie Vinches
Session: Poster Display session 1
Resources:
Abstract
5273 - Specialist Palliative Care (SPC) in Haematological Malignancy: Establishing practices in a UK Tertiary Cancer Centre (TCC)
Presenter: Emma Kedgley
Session: Poster Display session 1
Resources:
Abstract
5864 - Evaluation of the relationship between the attachment styles and psychological resilience of cancer patients receiving chemotherapy
Presenter: Fatma Bugdayci Basal
Session: Poster Display session 1
Resources:
Abstract
770 - Gefitinib along with Methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients
Presenter: Vidya Dusi
Session: Poster Display session 1
Resources:
Abstract
4232 - High intensity end-of-life care in pediatrics, adolescent and young adult patients with cancer using an administrative database.
Presenter: Seiko Bun
Session: Poster Display session 1
Resources:
Abstract
4845 - Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Presenter: Deniz Can Guven
Session: Poster Display session 1
Resources:
Abstract
3270 - Internet-based stepped care for individuals with cancer and concurrent anxiety or depression symptoms – results from a randomized controlled trial
Presenter: Birgitta Johansson
Session: Poster Display session 1
Resources:
Abstract
5503 - Impact of Cognitive-Behavioral-Therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)
Presenter: Daniela Tregnago
Session: Poster Display session 1
Resources:
Abstract
5553 - Cytokine genetic variations and worse quality of life among family caregivers of head and neck cancer patients in palliative care
Presenter: Daniel Pequeno
Session: Poster Display session 1
Resources:
Abstract